Advertisement

Topics

Pfizer Release: IBRANCE (Palbociclib) Receives FDA Regular Approval And Expanded Indication For First-Line HR+, HER2- Metastatic Breast Cancer

20:00 EDT 2 Apr 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Pfizer Release: IBRANCE (Palbociclib) Receives FDA Regular Approval And Expanded Indication For First-Line HR+, HER2- Metastatic Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Pfizer Release: IBRANCE (Palbociclib) Receives FDA Regular Approval And Expanded Indication For First-Line HR+, HER2- Metastatic Breast Cancer"

Quick Search
Advertisement